Nucleai Partners with GoPath Diagnostics to Offer AI-Based Digital Pathology Solutions for Clinical Research and Diagnosis
Shots:
- Nucleai & GoPath have partnered to combine AI algorithms & digital pathology viewer with GoPath's LIMS & LMS facilitating real-time data sharing at scale for centralized, on-demand AI analysis to improve clinicians' assessments of diagnostic pathology cases
- The companies will develop predictive AI algorithms through research projects to generate insights for various oncology & immunology indications incl. prostate cancer & inflammatory bowel disease (IBD)
- Furthermore, the partnership will provide access to real-world training & validation datasets, comprehensive molecular & pathology services as well as advanced AI capabilities facilitating new & current collaborations with sponsored clinical trials
Ref: Businesswire | Image: Nucleai
Related News:- Mainz Biomed and TomaLab Collaborate to Enhance the Diagnosis of Colorectal Cancer Using ColoAlert
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
